RxDoctor Payments DataLook up a doctor →

Jessica Kaffenberger, MD

Dermatology · Columbus, OHNPI 1588977912

Payments from drug & device makers

$3,225,861in general payments, 2019–2025

Across 937 payments — averaging $3442.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.1M
  • AbbVie$504K
  • Incyte Corporation$404K
  • Regeneron$365K
  • UCB SA$281K
  • Amgen$211K
  • plus $345K from 7 others
$33,580in research payments, 2019–2025

Across 5 payments — averaging $6716.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$34K

What the payments were for

  • Consulting fees$4,99599%
  • Food & beverage$711%

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly35$1,115,323
AbbVie108$504,065
Incyte Corporation526$404,053
Regeneron161$365,366
UCB SA17$280,633
Amgen15$211,086
Pfizer40$93,604
Novartis5$91,712
Bristol Myers Squibb3$72,053
Janssen Research & Development, LLC23$57,633
E.r. Squibb & Sons, L.L.C.2$27,941
Boehringer Ingelheim1$2,325
Johnson & Johnson1$67

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,225,861 in reported general payments places this provider in the 95th percentile of 460 dermatology providers in Ohio.

See all dermatology providers in Ohio

Medicare billing

Part B allowed, 2024
$103,787
Medicare patients
448
Services billed
1,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$312,095
Skyrizi PenRisankizumab-Rzaa12$219,458
Humira PenAdalimumab13$164,755
TremfyaGuselkumab13$149,211
OtezlaApremilast25$122,188
Tacrolimus41$5,846
Fluorouracil53$4,057
Clobetasol Propionate34$3,015
Acitretin14$2,159
Ciclopirox39$1,755
Fluocinolone AcetonideFluocinolone/Shower Cap13$1,611
Fluocinonide33$1,394
Doxycycline Monohydrate47$1,045
Metronidazole15$992
ValacyclovirValacyclovir Hcl28$876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Tremfya$67$461,30626 claims
AmgenOtezla$211,086$122,18825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 460 dermatology providers in Ohio.

Other dermatology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →